Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- WHO classification of tumours: soft-tissue and bone tumours. International Agency for Research on Cancer, Geneva, Switzerland2020
- Outcome and prognosis in retroperitoneal soft-tissue sarcoma.Int J Radiat Oncol Biol Phys. 1994; 29: 1005-1010
- Adult sarcoma management in ontario.Expert Panel Rep 2009. 2009;
- Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft-tissue sarcomas.Ann Oncol. 2004; 15: 307-315
- Soft-tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021; 32: 1348-1365
- Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the transatlantic australasian RPS working group.Ann Surg Oncol. 2021; 28: 7873-7888
- The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.Ann Surg. 1982; 196: 305
- The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft-tissue sarcoma of the extremity.Ann Surg Oncol. 2005; 12: 10-17
- Major amputations for extremity soft-tissue sarcoma.Ann Surg Oncol. 2018; 25: 387-393
- Primary soft-tissue sarcoma of the extremities in adults.J Br Surg. 1995; 82: 1208-1212
- Are radical compartmental resections for retroperitoneal sarcomas justified?.Ann Surg Oncol. 2010; 17: 1481-1484
- The problem of local recurrence after treatment of soft-tissue sarcoma.Ann Surg. 1968; 168: 47
- Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft-tissue sarcoma.J Clin Oncol. 1996; 14: 859-868
- Efficacy of adjuvant radiation therapy in the treatment of soft-tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.Ann Surg Oncol. 2014; 21: 2484-2489
- Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.The Lancet. 2002; 359: 2235-2241
- Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft-tissue sarcoma.Radiother Oncol. 2005; 75: 48-53
- Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of Radiation Therapy Oncology Group RTOG-0630 trial.J Clin Oncol. 2015; 33: 2231
- Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft-tissue sarcoma.Cancer. 2013; 119: 1878-1884
- Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial.JAMA Oncol. 2021; 7: e205865
- Retroperitoneal sarcomas and their management.Arch Surg. 1995; 130: 1104-1109
- Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum.Ann Surg. 1990; 212: 51-59
- Prognostic factors predicting survival in the treatment of retroperitoneal sarcoma.Eur J Surg Oncol. 2000; 26: 552-555
- Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma.Ann Surg Oncol. 2002; 9: 346-354
- Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma.J Clin Oncol. 2003; 21: 3092-3097
- Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate-or high-grade retroperitoneal soft-tissue sarcoma.Ann Surg Oncol. 2006; 13: 508-517
- Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial.Radiother Oncol. 2014; 110: 165-171
- Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft-tissue sarcoma: interim analysis.BMC cancer. 2014; 14: 1-12
- Preliminary results of phase 2 trial of preoperative image guided intensity modulated proton radiation therapy (IMPT) with simultaneously integrated boost (SIB) to the high-risk margin for retroperitoneal sarcomas (RPS).Wolters Kluwer Health, Philadelphia, PA2021
- Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2020; 21: 1366-1377
Callegaro D, RC AT, Strauss D, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: trial (STRASS) versus off-trial (STREXIT) results. Paper presented at: CTOS Annual Meeting2020.
- Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group.Ann Surg. 2016; 263: 1002-1009
- Adjuvant chemotherapy for adult soft-tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.J Clin Oncol. 2001; 19: 1238-1247
- Ifosfamide in the adjuvant therapy of soft-tissue sarcomas.Oncology. 2003; 65: 80-84
- Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data.The Lancet. 1997; 350: 1647-1654
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.Cancer. 2008; 113: 573-581
- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.Lancet Oncol. 2012; 13: 1045-1054
- The impact of chemotherapy on survival of patients with extremity and trunk wall soft-tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.Eur J Cancer. 2019; 109: 51-60
- sarcoma Full-dose neoadjuvant anthracycline+ ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft-tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial.Ann Oncol. 2016; 27: vi587
- Short, full-dose adjuvant chemotherapy in high-risk adult soft-tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.J Clin Oncol. 2012; 30: 850-856
- A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’adult soft-tissue sarcoma.Eur J Cancer. 2001; 37: 1096-1103
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.Lancet Oncol. 2017; 18: 812-822
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 1493-1501
- Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.J Clin Oncol. 2019; 37: 11015
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.Lancet Oncol. 2019; 20: 837-848
- Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial.JAMA Oncol. 2020; 6: 1778-1782
- Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).Am J Clin Oncol. 2020; 38: 11505
- SU2C-SARC032: a phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft-tissue sarcoma.J Clin Oncol. 2018; 36: TPS11588
- Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumabsarcoma-associated immune infiltrate and Anti-PD1 therapy.Clin Cancer Res. 2020; 26: 1258-1266
- A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.Am J Clin Oncol. 2020; 38: 11509
- B cells are associated with survival and immunotherapy response in sarcoma.Nature. 2020; 577: 556-560
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med. 2002; 347: 472-480
- Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.J Clin Oncol. 2008; 26: 620-625
- Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial.Ann Surg. 2013; 258: 422
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Lancet. 2009; 373: 1097-1104
- Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.J Clin Oncol. 2014; 32: 1563
- Time to definitive failure to the first tyrosine kinase inhibitor in localized gi stromal tumors treated with imatinib as an adjuvant: a european organisation for research and treatment of cancer soft-tissue and bone sarcoma group intergroup randomized trial in collaboration with the australasian gastro-intestinal trials group, UNICANCER, french sarcoma group, italian sarcoma group, and spanish group for research on sarcomas.J Clin Oncol. 2015; 33: 4276-4283
- One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.JAMA. 2012; 307: 1265-1272
- Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up.JAMA Oncol. 2020; 6: 1241-1246
- Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial.J Clin Oncol. 2016; 34: 244-250
- Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate-or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial.JAMA Oncol. 2018; 4: e184060
- Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.Ann Surg Oncol. 2007; 14: 14-24
- Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.World J Surg. 2010; 34: 2090-2097
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.J Surg Oncol. 2009; 99: 42-47
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.Ann Surg Oncol. 2012; 19: 1074-1080
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.Br J Cancer. 2017; 117: 25-32
- A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.Ann Surg Oncol. 2009; 16: 910-919
Article info
Publication history
Published online: November 03, 2022
Footnotes
Conflicts of Interest: none.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
